Facebook
Twitter
LinkedIn
ForwardOctober 10 - 11, 2014 - Taj Hotel, Boston, MA
Course Directors: Gersh, Bernard J., M.B., Ch.B., D.Phil. | Rihal, Charanjit S., M.D.
Program Schedule
Program schedules are subject to change without notice.
Friday, October 10
| Time | Topic |
|---|---|
| 12:00 p.m. | Registration |
| 1:00 p.m. | Welcome and Introductions Course Directors Focus on Intervention |
| 1:15 p.m. | Advanced Valvular Heart Disease: Transcatheter Aortic Valve Replacement and Transcatheter Mitral Valve Repair in Collaboration with Cardiac Surgical Expertise and the “Hybrid Operating Room” Deepak L. Bhatt, M.D., M.P.H., Charanjit S. Rihal, M.D., John Byrne, M.D., and Rakesh M. Suri, M.D., Ph.D. |
| 1:55 p.m. | Discussion / Questions and Answers |
| 2:10 p.m. | Multidrug Treatment of Hypertension and Renal Denervation Therapy for Resistant Hypertension (Including Definition of “Resistant”) Rajiv Gulati, M.D., Ph.D., and Deepak L. Bhatt, M.D., M.P.H. |
| 2:50 p.m. | Discussion / Questions and Answers |
| 3:05 p.m. | Hypertrophic Cardiomyopathy: Genetics, Genetic Testing, Prognosis, and Interventional Options with Implantable Defibrillators, Alcohol Septal Ablation, and Surgical Myectomy Christine E. Seidman, M.D., and Hartzell V. Schaff, M.D. |
| 3:45 p.m. | Discussion / Questions and Answers Cardiovascular Imaging Session Chair: Samuel Z. Goldhaber, M.D. |
| 4:00 p.m. | Multimodality Cardiovascular Imaging: Echocardiography, Nuclear Imaging, Coronary CT and Magnetic Resonance Jae K. Oh, M.D. and Marcelo Di Carli, M.D. |
| 4:40 p.m. | Discussion / Questions and Answers |
| 5:00 p.m. | Adjourn – Break Until Keynote Lecture Followed by Dinner Keynote Lecture – Ballroom |
| 6:30 p.m. | Fifty Years of Innovation in Cardiovascular Medicine: A Personal Perspective Eugene Braunwald, M.D. |
| 7:15 p.m. | Discussion / Questions and Answers |
| 7:30 p.m. | Dinner (Roof Top, Taj Hotel) |
Saturday, October 11
| Time | Topic |
|---|---|
| 7:30 a.m. | Continental Breakfast Atrial Fibrillation: Fundamental Considerations, Electrophysiological Intervention, and Novel Oral Anticoagulants for Stroke Prevention Session Co-Chairs: William G. Stevenson, M.D., and Douglas L. Packer, M.D. |
| 8:30 a.m. | Atrial Fibrillation: Rate Versus Rhythm Control William G. Stevenson, M.D. |
| 8:50 a.m. | Atrial Fibrillation: Risk Stratification and the Role of Biomarkers Bernard J. Gersh, M.B., Ch.B., D.Phil. |
| 9:10 a.m. | Discussion / Questions and Answers |
| 9:25 a.m. | Atrial Fibrillation: Ablation and Device Therapy (Including the “Watchman” and Other Devices) Laurence Epstein, M.D., and Douglas L. Packer, M.D. |
| 10:05 a.m. | Discussion / Questions and Answers |
| 10:15 a.m. | Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Dabigatran (RE-LY), Rivaroxaban (ROCKET-AF), Apixaban (ARISTOTLE), Edoxaban (ENGAGE) Christian T. Ruff, M.D. |
| 10:35 a.m. | Refreshment Break Advanced Heart Failure Session Co-Chairs: Marc Pfeffer, M.D., Ph.D. and Barry A. Borlaug, M.D. |
| 11:00 a.m. | Heart Failure with Preserved Ejection Fraction Barry A. Borlaug, M.D., and Marc Pfeffer, M.D., Ph.D. |
| 11:30 a.m. | Ventricular Assist Devices: Bridge to Transplant, Destination Therapy, Bridge to Decision, or Bridge to “Cure”? Mandeep Mehra, M.D. |
| 11:45 a.m. | Cardiac Transplantation and the Artificial Heart: Criteria, Decision-Making, and Outcomes Sudhir S. Kushwaha, M.D. |
| 12:00 p.m. | The Link Between Sleep Disordered Breathing and Heart Failure: Synergistic Therapeutic Approaches Virend K. Somers, M.D., Ph.D. |
| 12:15 p.m. | Anticipating the End of Life Lynne W. Stevenson, M.D. |
| 12:30 p.m. | Lunch Inflammation and Cardiovascular Medicine Session Co-Chairs: Samuel Z. Goldhaber, M.D., and Peter Libby, M.D. |
| 1:50 p.m. | Inflammation Overview: Triggers, Pathophysiology, and Relation Between Inflammation and Thrombosis Peter Libby, M.D. |
| 2:05 p.m. | Inflammation: The Microvasculature Amir Lerman, M.D. |
| 2:20 p.m. | Inflammation: Acute Coronary Syndromes and Trials of Cardiovascular Inflammation Reduction Paul M. Ridker, M.D., M.P.H. |
| 2:35 p.m. | Inflammation: Pulmonary Embolism and Deep Vein Thrombosis Samuel Z. Goldhaber, M.D. |
| 2:50 p.m. | Discussion / Questions and Answers Special Challenges with Disease of the Aorta and Aortic Valve Session Co-Chairs: Charanjit S. Rihal, M.D. and Deepak L. Bhatt, M.D., M.P.H. |
| 3:10 p.m. | Integrating Individualized Medicine Into Routine Clinical Care Gianrico Farrugia, M.D. |
| 3:25 p.m. | Low Flow, Low Gradient Aortic Stenosis David R. Holmes, Jr., M.D. |
| 3:40 p.m. | Biscuspid Aortic Valve Deepak L. Bhatt, M.D., M.P.H. |
| 3:55 p.m. | Discussion / Questions and Answers The Future of Regenerative Medicine Session Co-Chairs: Richard T. Lee, M.D. and Robert D. Simari, M.D. |
| 4:10 p.m. | Remarks/Discussion/Q&A The Future of Regenerative Medicine Richard T. Lee, M.D., and Robert D. Simari, M.D. |
| 4:50 p.m. | Wrap-Up and Concluding Remarks Drs. Libby, Gersh, Goldhaber, and Rihal |
| 5:00 p.m. | Adjourn |
Faculty
Course Directors
- Peter Libby, M.D.
- Bernard J. Gersh, M.B., Ch.B., D.Phil.
- Samuel Z. Goldhaber, M.D.
- Charanjit S. Rihal, M.D.
Mayo Clinic Faculty
- Barry A. Borlaug, M.D.
- Gianrico Farrugia, M.D.
- Rajiv Gulati, M.D., Ph.D.
- David R. Holmes Jr., M.D.
- Sudhir S. Kushwaha, M.D.
- Amir Lerman, M.D.
- Jae K. Oh., M.D.
- Douglas L. Packer, M.D.
- Hartzell V. Schaff, M.D.
- Robert D. Simari, M.D.
- Virend Somers, M.D., Ph.D.
- Rakesh M. Suri, M.D., D.Phil.
Brigham and Women's Faculty
- Deepak L. Bhatt, M.D., M.P.H.
- Eugene Braunwald, M.D.
- John Byrne, M.D.
- Marcelo Di Carli, M.D.
- Laurence Epstein, M.D.
- Richard T. Lee, M.D
- Marc Pfeffer, M.D., Ph.D.
- Mandeep Mehra, M.D.
- Paul M. Ridker, M.D.
- Christian T. Ruff, M.D.
- Christine E. Seidman, M.D.
- Lynne W. Stevenson, M.D.
- William G. Stevenson, M.D.
- Frederick Welt, M.D.
Faculty Disclosure
As a provider accredited by ACCME, Mayo Clinic College of Medicine (Mayo School of Continuous Professional Development) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentation.